Breaking Finance News

Agilent Technologies Inc. (NYSE:A) target price raised to $8.00, reported today by Morgan Stanley

Yesterday Agilent Technologies Inc. (NYSE:A) traded 0.29% higher at $67.52. The company’s 50-day moving average is $64.63 and its 200-day moving average is $59.42. The last stock close price is up 12.01% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 738,344 shares of the stock were exchanged, down from an average trading volume of 1,620,990

Agilent Technologies Inc. (NYSE:A) had its target price raised to $8.00 by Morgan Stanley in a report released 11/14/2017. The new target price indicates a possible downside of -0.88% based on the company's last stock close price.

Previously on Monday October 09, 2017, Bank of America (Merrill Lynch) reported about Agilent Technologies Inc. (NYSE:A) raised the target price from $6.00 to $7.00. At the time, this indicated a possible downside of -0.89%.

See Chart Below

Agilent Technologies Inc. (NYSE:A)

Agilent Technologies Inc. has a 52 week low of $42.92 and a 52 week high of $66.77 with a P/E ratio of 34.32 The company’s market cap is currently $0.

In addition to Morgan Stanley reporting its target price, a total of 14 firms have reported on the stock. The consensus target price is $45.86 with 6 firms rating the stock a strong buy, 4 firms rating the stock a buy, 6 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Agilent Technologies Inc. (NYSE:A)

Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.